SCHEMBL7681002

SCHEMBL7681002

COc1ccc(C(=O)c2c(C)cc(C(C)C(=O)O)n2C)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
TPMT P51580 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7676850 0.89 CYP2C19 (0.48) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7684691 0.82 CYP2C19 (0.46) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7676990 0.81 PTGS2 (0.46) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7674668 0.80 PTGS2 (0.49) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7680560 0.79 CYP1A2 (0.42) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7674446 0.79 PTGS2 (0.60) TSHRCYP1A2CYP2C9CYP2C19PTGS1
SCHEMBL7681922 0.79 PTGS2 (0.44) TSHRCYP1A2CYP3A4PTGS1PTGS2
SCHEMBL7681020 0.78 PTGS2 (0.65) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7674658 0.76 PTGS2 (0.41) TSHRCYP1A2PTGS1PTGS2CA1
SCHEMBL7680616 0.76 SRD5A2 (0.44) TSHRCYP1A2PTGS2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A TSHR 2892/4885CYP1A2 1487/4885CYP3A4 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.